The role of interleukin-12 in the heavy metal-elicited immunomodulation: relevance of various evaluation methods

• Main Author: Hemdan Nasr YA
• Format: Article
• Language: English
• Published: BMC 2008-11-01
• Series: Journal of Occupational Medicine and Toxicology
• Online Access: http://www.occup-med.com/content/3/1/25

<p>Abstract</p> <p>Background</p> <p>Increasing evidence exists that heavy metals modulate T helper cell (Th) responses and thereby elicit various pathological manifestation. Interleukin (IL)-12, a crucial innate cytokine, was found to be regulated by such xenobiotic agents. This study aimed at testing whether IL-12 profiles may be indicative of heavy metals-induced immunomodulation.</p> <p>Methods</p> <p>Human immunocompetent cells, activated either by monoclonal antibodies or heat-killed <it>Salmonella enterica</it>, were cultured in the absence or presence of cadmium (Cd) acetate or mercuric (Hg) chloride. <it>In vivo </it>experiments were set up where BALB/c mice were exposed to sub-lethal doses of Cd or Hg salts for 3 or 5 weeks. Cytotoxicity was assessed by MTT-reduction assay. Modulation of cytokine profiles was evaluated by enzyme-linked immunosorbent assay (ELISA), cytometric bead-based array (CBA) and real-time polymerase chain reaction (RT-PCR); the relevance of these methods of cytokine quantification was explored.</p> <p>Results</p> <p>Modulation of IL-12 profiles in Cd- or Hg-exposed human PBMC was dose-dependent and significantly related to IFN-γ levels as well as to the Th1- or Th2-polarized responses. Similarly, skewing the Th1/Th2 ratios <it>in vivo </it>correlated significantly with up- or down-regulation of IL-12 levels in both cases of investigated metals.</p> <p>Conclusion</p> <p>It can be inferred that: (i) IL-12 profiles alone may represent a relevant indicator of heavy metal-induced immune modulation; (ii) evaluating cytokine profiles by CBA is relevant and can adequately replace other methods such as ELISA and RT-PCR in basic research as well as in immune diagnostics; and (iii) targeting IL-12 in therapeutic approaches may be promising to modify Th1/Th2-associated immune disorders.</p>